Increased Energy Expenditure and Protection From Diet-Induced Obesity in Mice Lacking the cGMP-Specific Phosphodiesterase PDE9

Cyclic nucleotides cAMP and cGMP are important second messengers for the regulation of adaptive thermogenesis. Their levels are controlled not only by their synthesis, but also their degradation. Since pharmacological inhibitors of cGMP-specific phosphodiesterase 9 (PDE9) can increase cGMP-dependent protein kinase signaling and uncoupling protein 1 expression in adipocytes, we sought to elucidate the role of PDE9 on energy balance and glucose homeostasis in vivo. Mice with targeted disruption of the PDE9 gene, Pde9a, were fed nutrient-matched high-fat (HFD) or low-fat diets. Pde9a−/− mice were resistant to HFD-induced obesity, exhibiting a global increase in energy expenditure, while brown adipose tissue (AT) had increased respiratory capacity and elevated expression of Ucp1 and other thermogenic genes. Reduced adiposity of HFD-fed Pde9a−/− mice was associated with improvements in glucose handling and hepatic steatosis. Cold exposure or treatment with β-adrenergic receptor agonists markedly decreased Pde9a expression in brown AT and cultured brown adipocytes, while Pde9a−/− mice exhibited a greater increase in AT browning, together suggesting that the PDE9-cGMP pathway augments classical cold-induced β-adrenergic/cAMP AT browning and energy expenditure. These findings suggest PDE9 is a previously unrecognized regulator of energy metabolism and that its inhibition may be a valuable avenue to explore for combating metabolic disease.

[1]  Dorothy D. Sears,et al.  PDE9 Inhibition Activates PPARα to Stimulate Mitochondrial Fat Metabolism and Reduce Cardiometabolic Syndrome , 2021, bioRxiv.

[2]  S. Collins,et al.  A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure. , 2020, Clinical science.

[3]  Craig M. Hales,et al.  Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. , 2020, NCHS data brief.

[4]  Kong Y. Chen,et al.  Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity , 2019, The Journal of Biological Chemistry.

[5]  A. Astrup,et al.  Atrial natriuretic peptide orchestrates a coordinated physiological response to fuel non shivering thermogenesis , 2019, bioRxiv.

[6]  B. Dubois,et al.  Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[7]  D. Rybin,et al.  PF‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study , 2018, Clinical and translational science.

[8]  R. Keefe,et al.  Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial , 2017, Schizophrenia bulletin.

[9]  K. Davis,et al.  Early and late complications of bariatric operation , 2018, Trauma Surgery & Acute Care Open.

[10]  M. Sand,et al.  The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers , 2018, European Neuropsychopharmacology.

[11]  K. Hosoda,et al.  Adipocyte-specific expression of C-type natriuretic peptide suppresses lipid metabolism and adipocyte hypertrophy in adipose tissues in mice fed high-fat diet , 2018, Scientific Reports.

[12]  S. Collins,et al.  Cardiac natriuretic peptides promote adipose ‘browning’ through mTOR complex-1 , 2018, Molecular metabolism.

[13]  M. Yoshimura,et al.  The thermogenic actions of natriuretic peptide in brown adipocytes: The direct measurement of the intracellular temperature using a fluorescent thermoprobe , 2017, Scientific Reports.

[14]  S. Collins,et al.  Second messenger signaling mechanisms of the brown adipocyte thermogenic program: an integrative perspective. , 2017, Hormone molecular biology and clinical investigation.

[15]  E. Lewandowski,et al.  Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance , 2017, Science Signaling.

[16]  Ana Kilić,et al.  Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism , 2017, Molecular metabolism.

[17]  M. Sand,et al.  A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers , 2017, Human psychopharmacology.

[18]  Huyuan Yang,et al.  What Is Already Known about This Subject What This Study Adds , 2022 .

[19]  Kong Y. Chen,et al.  Persistent metabolic adaptation 6 years after “The Biggest Loser” competition , 2016, Obesity.

[20]  Jong Hun Kim,et al.  Human ‘brite / beige’ adipocytes develop from capillary networks and their implantation improves metabolic homeostasis in mice , 2015, Nature Medicine.

[21]  A. Pfeifer,et al.  cGMP and Brown Adipose Tissue. , 2016, Handbook of experimental pharmacology.

[22]  A. Martí,et al.  Comorbidity associated with obesity in a large population: The APNA study. , 2015, Obesity research & clinical practice.

[23]  D. Joanisse,et al.  Defective Natriuretic Peptide Receptor Signaling in Skeletal Muscle Links Obesity to Type 2 Diabetes , 2015, Diabetes.

[24]  Thomas Danner,et al.  Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease , 2015, Nature.

[25]  Alexander Pfeifer,et al.  Brown, beige, and white: the new color code of fat and its pharmacological implications. , 2015, Annual review of pharmacology and toxicology.

[26]  T. Nicholas,et al.  A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. , 2014, Current Alzheimer research.

[27]  H. Ke,et al.  Advances in targeting cyclic nucleotide phosphodiesterases , 2014, Nature Reviews Drug Discovery.

[28]  J. Gutkowska,et al.  Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice , 2014, Diabetologia.

[29]  Crystal M. Riley,et al.  Young adult weight trajectories through midlife by body mass category , 2013, Obesity.

[30]  Ana Kilić,et al.  Increased cGMP promotes healthy expansion and browning of white adipose tissue , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  S. Collins,et al.  Heart hormones fueling a fire in fat , 2013, Adipocyte.

[32]  J. Segal,et al.  Strategies to Prevent Weight Gain Among Adults [Internet] , 2013 .

[33]  P. Even,et al.  Integrative and Translational Physiology : Integrative Aspects of Energy Homeostasis and Metabolic Diseases Indirect calorimetry in laboratory mice and rats : principles , practical considerations , interpretation and perspectives , 2012 .

[34]  B. Spiegelman,et al.  Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human , 2012, Cell.

[35]  G. Ailhaud,et al.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. , 2012, The Journal of clinical investigation.

[36]  S. Going,et al.  A review of evidence-based strategies to treat obesity in adults. , 2011, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[37]  E. Degerman,et al.  Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity , 2011, Nutrition & Diabetes.

[38]  J. Gromada,et al.  Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. , 2011, Biochemical and biophysical research communications.

[39]  D. Kass,et al.  Phosphodiesterases and cardiac cGMP: evolving roles and controversies. , 2011, Trends in pharmacological sciences.

[40]  Mami Matsushita,et al.  Brown Adipose Tissue, Whole‐Body Energy Expenditure, and Thermogenesis in Healthy Adult Men , 2011, Obesity.

[41]  J. Orava,et al.  Functional brown adipose tissue in healthy adults. , 2009, The New England journal of medicine.

[42]  W. D. van Marken Lichtenbelt,et al.  Cold-activated brown adipose tissue in healthy men. , 2009, The New England journal of medicine.

[43]  K. Kristiansen,et al.  Human Multipotent Adipose‐Derived Stem Cells Differentiate into Functional Brown Adipocytes , 2009, Stem cells.

[44]  K. Nakao,et al.  Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity , 2009, Diabetes.

[45]  E. Palmer,et al.  Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.

[46]  J. Rottman,et al.  Chronic Treatment With Sildenafil Improves Energy Balance and Insulin Action in High Fat–Fed Conscious Mice , 2007, Diabetes.

[47]  C. Dani,et al.  Adipocyte differentiation of multipotent cells established from human adipose tissue. , 2004, Biochemical and biophysical research communications.

[48]  I. Arechaga,et al.  The Mitochondrial Uncoupling Protein UCP1: A Gated Pore , 2001, IUBMB life.

[49]  U. Walter,et al.  Analysis and Regulation of Vasodilator-stimulated Phosphoprotein Serine 239 Phosphorylation in Vitro and in Intact Cells Using a Phosphospecific Monoclonal Antibody* , 1998, The Journal of Biological Chemistry.

[50]  J. Beavo,et al.  Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases* , 1998, The Journal of Biological Chemistry.